About BCLI

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Pharmaceutical Preparation Manufacturing

BCLI is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VXF Vanguard Extended Market ETF 6.8 B 6.8E+09 3,242 3242 0.0% 1E-05 92 K 92471
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.6 B 1.85536E+10 3,550 3550 0.0% 0 47 K 47146
IWC iShares Microcap ETF 914.4 M 9.14374E+08 1,451 1451 0.02% 0.0002 207 K 206639

Wait, Before You Leave...